Open AccessA Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD‐FL)
Author(s) -
Salles Gilles,
Schuster Stephen J.,
Fischer Luca,
Kuruvilla John,
Patten Piers E. M.,
Tresckow Bastian,
Smith Sonali,
JiménezUbieto Ana,
Davis Keith L.,
Nagar Saurabh,
Zhang Jie,
Bollu Vamsi,
Jousseaume Etienne,
Ramos Roberto,
Wang Yucai,
Link Brian K.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/hs9.0000000000000745
Subject(s) - medicine , follicular lymphoma , refractory (planetary science) , retrospective cohort study , rituximab , confidence interval , cohort , oncology , lymphoma , surgery , biology , astrobiology
This study (ReCORD‐FL) sought to construct a historical control cohort to augment single‐arm trials in relapsed/refractory follicular lymphoma (r/r FL). A retrospective study in 10 centers across North America and Europe was conducted. Adults with grade 1–3A FL were required to be r/r after ≥2 therapy lines including an anti‐CD20 and an alkylator. After first becoming r/r, patients were required to initiate ≥1 additional therapy line, which defined the study index date. Endpoints were observed from start of each therapy line (including index line) until death, last follow‐up, or December 31, 2020. Endpoints were complete response (CR) rate, overall response rate (ORR), time to next treatment or death (TNT‐D), event‐free survival (EFS), and overall survival (OS). One hundred eighty‐seven patients were identified. Most patients’ (80.2%) index therapy occurred in third line (3L) (range, 3L–6L). Median follow‐up from FL diagnosis was 9 years (range, 1–21 years). CR and ORR to the index therapy were 39.0% and 70.6%, respectively. Median (95% confidence interval) EFS from index was 14.6 (11.0‐18.0) months; median OS from index was 10.6 years. Outcomes worsened across successive treatment lines and for patients who were double refractory (r/r to both an anti‐CD20 monoclonal antibody and an alkylator) or POD24 (progressed ≤24 months after front‐line anti‐CD20) at index. Findings demonstrate the unmet need of FL patients with multiply relapsed, double refractory, or POD24 disease. Based on robustness of the historical data collected and comparability with a previous study (SCHOLAR‐5), ReCORD‐FL presents a valuable source of control data for comparative studies in r/r FL.